J. Goldman & Co’s United Therapeutics UTHR Stock Holding History

J. Goldman & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-24,622	Closed	-$5.8M	–	498
2022 Q2	$5.8M	Buy	+24,622	New	+$5.01M	0.28%	94

Other funds holding UTHR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

J. Goldman & Co's UTHR Position: Q3 2022 in Review

J. Goldman & Co sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 24,622 shares — an estimated $5.8M sold.

J. Goldman & Co first reported a position in UTHR in Q2 2022 and held it in 1 quarter. The position peaked at $5.8M in Q2 2022. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

J. Goldman & Co reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
J. Goldman & Co sold 24,622 United Therapeutics shares in Q3 2022, an estimated $5.8M.
J. Goldman & Co first reported a position in United Therapeutics in Q2 2022 and held it in 1 quarter.
J. Goldman & Co's United Therapeutics position peaked at $5.8M in Q2 2022.
459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.